MedTrace Logo

Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus

NCT00739635 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 411

Last updated 2016-02-04

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.

Conditions

  • Subjective Tinnitus

Interventions

DRUG

Neramexane mesylate

Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day

DRUG

Placebo

Double-blind treatment period of 17 weeks placebo

Sponsors & Collaborators

  • Merz Pharmaceuticals GmbH

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Austria
  • Germany
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00739635 on ClinicalTrials.gov